Dr. Emily Brouwer
Dr. Emily Brouwer

Assistant Professor

Recent Publications

  • Brouwer Emily Suzanne, Moga Daniela Claudia, Eron, Jr J J, Napravnik S. (2015). Evaluating the incident user design in the HIV population: incident use versus naive?. Pharmacoepidemiology and drug safety, 24(3), 297-300.
  • Brouwer Emily Suzanne, Policastri Anne, Moga Daniela Claudia. (2015). Using administrative data for your research project: 10 considerations before you begin. Am J Health Syst Pharm, 72(3), 184-7.
  • Moga Daniela Claudia, Abner Erin, Brouwer Emily Suzanne. (2015). Dementia and "obesity paradox": is this for real or are we missing something? An epidemiologist's perspective. Journal of the American Medical Directors Association, 16(1), 78-9.
  • Brouwer Emily Suzanne, Moga Daniela Claudia, Eron J, Napravnik S. (2014). Evaluating the incident user design in the HIV population: incident use versus naive?. Pharmacoepidemiol Drug Saf, Epub ahead of print,
  • Brouwer Emily Suzanne. (2014). Women living with HIV and healthcare reform. J Womens Health (Larchmt), 23(8), 715.
  • Hickson R, Brouwer Emily Suzanne, Brancato C, Moga Daniela Claudia. (2014). Factors Predicting Beta-Blocker Treatment After Myocardial Infarction in Patients with Type 2 Diabetes. Value in Health, 3(17), A104.
  • Brouwer Emily Suzanne, Napravnik S, Eron J, Stalzer B, Floris-Moore M, Simpson R J, Stürmer T. (2014). Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients. Epidemiology, 25(3), 406-17.
  • Brouwer Emily Suzanne, Array Sarah. (2014). Sex differences in benzodiazepine use in the HIV-infected population. AIDS Care, 26(10), 1218-22.
  • Brouwer Emily Suzanne, Wixson S, Moga Daniela Claudia. (2014). Predictors of Receiving Guideline-Recommended Antiretroviral Treatment: Type of Provider Influences the Provision of Optimum HIV Treatment. Pharmacoepidemiol Drug Saf, 23(S1), 1-497.
  • Moga Daniela Claudia, Brouwer Emily Suzanne, Ekinci E, Zhang Xiping. (2013). Evaluation of Pharmacological Management for Type 2 Diabetes Post-Myocardial Infarction. Value Health, 16(3), A277.